Drugs / SHR-2017
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06380881 | May 2024 → Aug 2025 | — | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05930704 | Jul 2023 → Apr 2025 | osteoporosis | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07028268 | Jun → Dec 2025 overdue | — | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-2017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05930704 ↗ |
| Route | Subcutaneous | “single subcutaneous dose of SHR-2017 injection” NCT05930704 ↗ |